EpCAM在前列腺癌中的表达及其相关临床意义(5)
[18] Went P，Vasei M，Bubendorf L，et al.Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon， stomach， prostate and lung cancers[J].British Journal of Cancer，2006，94(1)：128.
[19] Long M D， Smiraglia D J，Campbell M J.The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer[J].Biomolecules，2017，7(1)：15.
[20] Poczatek R B，Myers R B，Manne U，et al.Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J].J Urol，1999，162(4)：1462-1466.
[21] Zellweger T，Ninck C，Bloch M，et al.Expression patterns of potential therapeutic targets in prostate cancer[J].International Journal of Cancer，2005，113(4)：619-628.
[22] Tayama S，Motohara T，Narantuya D，et al.The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer[J].Oncotarget，2017，8(27)：44312-44325.
[23] Zheng X，Fan X，Fu B，et al.EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance[J].Cancer Research，2017，77(2)：482.
(收稿日期：2019-03-25) (本文編辑：周亚杰), 百拇医药(张继君 张桂平 韩小璐 刘薇薇 陶丽丽)
[19] Long M D， Smiraglia D J，Campbell M J.The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer[J].Biomolecules，2017，7(1)：15.
[20] Poczatek R B，Myers R B，Manne U，et al.Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J].J Urol，1999，162(4)：1462-1466.
[21] Zellweger T，Ninck C，Bloch M，et al.Expression patterns of potential therapeutic targets in prostate cancer[J].International Journal of Cancer，2005，113(4)：619-628.
[22] Tayama S，Motohara T，Narantuya D，et al.The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer[J].Oncotarget，2017，8(27)：44312-44325.
[23] Zheng X，Fan X，Fu B，et al.EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance[J].Cancer Research，2017，77(2)：482.
(收稿日期：2019-03-25) (本文編辑：周亚杰), 百拇医药(张继君 张桂平 韩小璐 刘薇薇 陶丽丽)